Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2004

Conditions
NSCLC
Interventions
DRUG

Doxorubicin HCl Inhalation Solution

DRUG

Docetaxel

DRUG

Cisplatin

Trial Locations (6)

10461

Montefiore Medical Center, The Bronx

43210

Arthur G James Cancer Hospital and Richard Solove Research Institute at Ohio State University, Columbus

53792

University of Wisconsin Cancer Center, Madison

89106

Southern Nevada Cancer Research Foundation, Las Vegas

89135

Nevada Cancer Institute, Las Vegas

06520

Yale University Cancer Center, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zivena

INDUSTRY

NCT00082472 - Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) | Biotech Hunter | Biotech Hunter